Free Cash Flow to Equity (FCFE)
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The period from 2018 to 2022 demonstrates a marked divergence between steady operational cash growth and highly volatile free cash flow to equity (FCFE). While the capacity to generate cash from core business operations expanded consistently, the actual cash available to shareholders fluctuated significantly, indicating substantial shifts in capital expenditures and financing activities.
- Operating Cash Flow Progression
- A sustained upward trend in net cash provided by operating activities is observed, increasing from 123,200 thousand US dollars in 2018 to 669,500 thousand US dollars by 2022. This represents a significant expansion in the capacity to generate liquidity from primary business functions, with only a marginal contraction occurring in 2021 before reaching a five-year peak in 2022.
- FCFE Volatility and Fluctuations
- Free cash flow to equity exhibits extreme instability over the analyzed period. Peak values were recorded in 2018 (892,700 thousand US dollars) and 2020 (1,182,800 thousand US dollars), which contrast sharply with significant troughs in 2019 (134,500 thousand US dollars) and 2021 (53,300 thousand US dollars). The absence of a linear trend in FCFE suggests that the cash available to equity holders is heavily influenced by non-operational cash movements.
- Operational vs. Equity Cash Flow Divergence
- A notable disconnect exists between operating cash and FCFE. In 2018 and 2020, FCFE significantly exceeded operating cash flow, which typically indicates substantial cash inflows from financing activities, such as debt issuance, or a significant decrease in capital expenditures. Conversely, in 2021 and 2022, FCFE remained below operating cash flow, suggesting that capital investments or debt repayments outweighed financing inflows during these periods.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Price to FCFE Ratio, Current
| No. shares of common stock outstanding | 386,373,935 |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in thousands) | 304,700) |
| FCFE per share | 0.79 |
| Current share price (P) | 81.09 |
| Valuation Ratio | |
| P/FCFE | 102.83 |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| Abbott Laboratories | 31.33 |
| Elevance Health Inc. | 24.43 |
| Intuitive Surgical Inc. | 60.69 |
| Medtronic PLC | 28.71 |
| UnitedHealth Group Inc. | 21.73 |
| P/FCFE, Sector | |
| Health Care Equipment & Services | 15.71 |
| P/FCFE, Industry | |
| Health Care | 26.69 |
Based on: 10-K (reporting date: 2022-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 386,413,690 | 388,262,536 | 384,709,452 | 366,376,568 | 360,007,068 | |
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in thousands)2 | 304,700) | 53,300) | 1,182,800) | 134,500) | 892,700) | |
| FCFE per share3 | 0.79 | 0.14 | 3.07 | 0.37 | 2.48 | |
| Share price1, 4 | 107.24 | 101.75 | 102.55 | 63.05 | 36.56 | |
| Valuation Ratio | ||||||
| P/FCFE5 | 136.00 | 741.20 | 33.35 | 171.75 | 14.74 | |
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| Abbott Laboratories | 26.11 | 24.52 | — | — | — | |
| Elevance Health Inc. | 14.26 | 11.07 | — | — | — | |
| Intuitive Surgical Inc. | 89.67 | 58.39 | — | — | — | |
| Medtronic PLC | 19.71 | 38.91 | — | — | — | |
| UnitedHealth Group Inc. | 12.57 | 20.11 | — | — | — | |
| P/FCFE, Sector | ||||||
| Health Care Equipment & Services | 16.47 | 22.14 | — | — | — | |
| P/FCFE, Industry | ||||||
| Health Care | 18.50 | 17.94 | — | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Data adjusted for splits and stock dividends.
3 2022 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 304,700,000 ÷ 386,413,690 = 0.79
4 Closing price as at the filing date of DexCom Inc. Annual Report.
5 2022 Calculation
P/FCFE = Share price ÷ FCFE per share
= 107.24 ÷ 0.79 = 136.00
6 Click competitor name to see calculations.
An analysis of the equity valuation metrics reveals a significant divergence between share price appreciation and the stability of Free Cash Flow to Equity (FCFE). While the market price of the shares exhibits a consistent upward trajectory, the underlying FCFE per share demonstrates extreme volatility, leading to erratic fluctuations in the P/FCFE ratio.
- Share Price Trend
- The share price experienced substantial growth over the five-year period, rising from 36.56 US$ in 2018 to 107.24 US$ by 2022. The most aggressive expansion occurred between 2018 and 2020, followed by a period of relative stabilization where the price remained above 100 US$.
- FCFE per Share Performance
- Cash flow to equity has been characterized by instability. After starting at 2.48 US$ in 2018, the value dropped sharply to 0.37 US$ in 2019, recovered to a peak of 3.07 US$ in 2020, and plummeted to a period low of 0.14 US$ in 2021, before finishing at 0.79 US$ in 2022.
- P/FCFE Ratio Interpretation
- The P/FCFE ratio exhibits extreme variance, largely driven by the volatility of the FCFE per share rather than movements in the share price. The ratio reached anomalous peaks of 171.75 in 2019 and 741.20 in 2021. These spikes correlate directly with years of diminished cash flow, indicating that the valuation ratio is highly sensitive to fluctuations in the company's ability to generate free cash flow for equity holders.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?